FZD1: Frizzled-1
Receptor for Wnt proteins.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on FZD1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Vantictumab | Phase 2 | OncoMed Pharmaceuticals | Antibody | AntagonistFrizzled-1 antagonist | 0 |
- Hair color0.51
- Spinal cord injury0.34
- Upper respiratory tract disorder0.32
- Humerus fracture0.22
- Self-injurious ideation0.20
- Male reproductive organ cancer0.19
- Glomerulonephritis0.16
- Gastric cancer0.15
- Smoking initiation0.14
- Bipolar disorder0.13
- Stroke disorder0.13
- Alcohol drinking0.13
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2346493, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q9UP38, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets